Ekasar Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 58.58%
- Profit Growth 98.05%
- Ebitda 37.44%
- Net Worth -11.19%
- Total Assets 17.65%
About Ekasar Lifesciences
Ekasar Lifesciences Private Limited (ELPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 May 2019 (Five years and nine months 7 days old ). Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ashish Sahu and Renu Dhiman serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24110CH2019PTC042517
-
Company No.
042517
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 May 2019
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
What products or services does Ekasar Lifesciences Private Limited offer?
Ekasar Lifesciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement.
Who are the key members and board of directors at Ekasar Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Sahu
|
Director | 10-May-2019 | Current |
|
Renu Dhiman
|
Director | 05-Sep-2022 | Current |
Financial Performance of Ekasar Lifesciences.
Ekasar Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 58.58% increase. The company also saw a substantial improvement in profitability, with a 98.05% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ekasar Lifesciences?
In 2020, Ekasar Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ekasar Lifesciences?
Unlock and access historical data on people associated with Ekasar Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ekasar Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ekasar Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
